Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Not Applicable

Recruiting

• Conditions: Atoptic Dermatitis
• Interventions: Drug: EVO756; Drug: Placebo control

• Registration Number: NCT07150845
• Lead Sponsor: Evommune, Inc.

Brief Summary

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-08-26
• Study First Submitted: 2025-08-28
• Study First Submitted QC: 2025-08-28
• Status Verified: 2025-09
• Study First Posted: 2025-09-02
• Last Update Submitted: 2025-09-15
• Last Update Posted: 2025-09-17
• Primary Completion: 2026-07
• Study Completion: 2026-07-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Chronic AD that has been present for ≥6 months
• Validated-Investigator's Global Assessment score of ≥3
• EASI of ≥16
• BSA of AD involvement of ≥10%

Exclusion Criteria

• Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
• Use of certain medications
• Presence of skin comorbidities or other condition(s) that may interfere with study assessments
• Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dose 1	EVO756	Orally administered EVO756, Dose 1
Dose 2	EVO756	Orally administered EVO756, Dose 2
Dose 3	EVO756	Orally administered EVO756, Dose 3
Placebo	Placebo control	Placebo control

Primary Outcome Measures

Name	Time	Method
Percentage change in Eczema Area and Severity Index (EASI) from Baseline	Week 12

Secondary Outcome Measures

Name	Time	Method
Mean and absolute changes in validated Investigator Global Assessment (vIGA) score from Baseline	Weeks 2, 4, 8, and 12
Percentage change in EASI from Baseline	Weeks 2, 4, and 8
Mean changes in EASI from Baseline	Week 2, 4, 8, and 12
Proportion of subjects with EASI-50, EASI-75, and EASI-90 from Baseline	Weeks 2, 4, 8, and 12
Proportion of subjects achieving a vIGA score of 0,1 with at least a 2-point reduction from Baseline	Weeks 2, 4, 8, and 12
Mean and percentage change from Baseline in the pruritus-NRS score	Weeks 2, 4, 8, and 12
Proportion of subjects achieving a 4-pt reduction in the pruritus-NRS score from Baseline	Week 2, 4, 8, and 12
Mean and percentage changes from Baseline in Body Surface Area (BSA) of affected area	Weeks 2, 4, 8, and 12
Occurrence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)	through Week 14

Trial Locations

Locations (11)

Equity Medical; 🇺🇸 New York, New York, United States

International Clinical Research - Murfreesboro; 🇺🇸 Murfreesboro, Tennessee, United States

Center for Dermatology Clinical Research; 🇺🇸 Fremont, California, United States

Metropolis Dermatology - Downtown Los Angeles; 🇺🇸 Los Angeles, California, United States

Skin and Beauty Center; 🇺🇸 Pasadena, California, United States

Skin Care Research, LLC; 🇺🇸 Boca Raton, Florida, United States

Driven Research, LLC; 🇺🇸 Coral Gables, Florida, United States

Skin Care Research - Hollywood Dermatology; 🇺🇸 Hollywood, Florida, United States

Empire Dermatology; 🇺🇸 East Syracuse, New York, United States

Skin Search of Rochester, Inc.; 🇺🇸 Rochester, New York, United States

Scroll for more (1 remaining)